Abstract
This study aimed to prepare a novel radiopharmaceutical for the detection of brain disorders at early stages in susceptible patients.Promazine hydrochloride was labeled with 125I by direct electrophilic substitution reaction with high labeling yields of 92.6 ± 3.24 %. The labeling yield and in vitro stability of 125I-promazine were determined by paper electrophoresis, paper chromatography (PC) and High performance liquid chromatography (HPLC). In vitro studies showed that the highest radiochemical yield of 125I-promazine (92.6±3.24%) was stable up to 6 h. Biodistribution studies showed that maximum uptakes of 125I-promazine in the brain of mice was 5.4 ± 0.18 % injected dose/g after 30 min post-injectionwhich is higher than that of 99mTc-HMPAO and 99mTc-ECD (2.25 and 4.7 %, respectively), so this confirms the high specificity and selectivity of this radiotracer for brain and could be used for brain imaging instead of the commercially available 99mTc-HMPAOand 99mTc-ECD.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
